Drug Profile


Alternative Names: ATI-5000; ATI-5923

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator ARYx Therapeutics
  • Developer Armetheon
  • Class Anticoagulants; Small molecules
  • Mechanism of Action Vitamin K epoxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Thromboembolism

Most Recent Events

  • 26 Aug 2016 Phase-III clinical trials in Thromboembolism (Prevention) in USA (PO) (Armetheon pipeline, August 2016)
  • 25 Aug 2016 Pharmacokinetics data from a phase I pharmacokinetics trial released by Armetheon
  • 25 Aug 2016 Armetheon initiates enrolment in a phase I pharmacokinetics trial in USA before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top